Exposure–Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema

Donidalorsen is a therapy designed to help prevent the painful swelling attacks that occur in people with hereditary angioedema (HAE). In collaboration with Ionis, Certara researchers analyzed clinical data from the Phase 3 OASIS-HAE study to better understand how the treatment works and how often it needs to be given. Their analysis showed that lower levels of a key protein called prekallikrein were linked to fewer HAE attacks, and that patients could safely move from monthly to every-other-month dosing while maintaining strong protection. These insights highlight a more flexible, convenient treatment approach for people living with this rare and challenging disease.